This company has been acquired
Checkpoint Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
James Oliviero
Chief executive officer
US$9.8m
Total compensation
| CEO salary percentage | 6.76% |
| CEO tenure | 9.7yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Sep 20
Checkpoint: Strong Data, But Comes With Risks
Sep 08Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M
Aug 12Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?
May 18Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions
Apr 18Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth
Feb 15Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results
Jan 28Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout
Nov 26Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans
Oct 30We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Jul 17Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data
Jul 14Checkpoint Therapeutics (CKPT) Investor Presentation - Slideshow
Jun 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$57m |
| Dec 31 2024 | US$10m | US$661k | -US$56m |
| Sep 30 2024 | n/a | n/a | -US$46m |
| Jun 30 2024 | n/a | n/a | -US$42m |
| Mar 31 2024 | n/a | n/a | -US$52m |
| Dec 31 2023 | US$2m | US$636k | -US$52m |
| Sep 30 2023 | n/a | n/a | -US$54m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$56m |
| Dec 31 2022 | US$2m | US$594k | -US$63m |
| Sep 30 2022 | n/a | n/a | -US$71m |
| Jun 30 2022 | n/a | n/a | -US$72m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$2m | US$540k | -US$57m |
| Sep 30 2021 | n/a | n/a | -US$37m |
| Jun 30 2021 | n/a | n/a | -US$31m |
| Mar 31 2021 | n/a | n/a | -US$26m |
| Dec 31 2020 | US$2m | US$515k | -US$23m |
| Sep 30 2020 | n/a | n/a | -US$22m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$22m |
| Dec 31 2019 | US$2m | US$480k | -US$25m |
| Sep 30 2019 | n/a | n/a | -US$28m |
| Jun 30 2019 | n/a | n/a | -US$32m |
| Mar 31 2019 | n/a | n/a | -US$33m |
| Dec 31 2018 | US$2m | US$450k | -US$36m |
Compensation vs Market: James's total compensation ($USD9.78M) is above average for companies of similar size in the US market ($USD2.67M).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
CEO
James Oliviero (49 yo)
Mr. James F. Oliviero, III, CFA has been the Chief Executive Officer and President of Checkpoint Therapeutics, Inc. since October 16, 2015 and also has been its Director since October 15, 2018. Mr. Olivier...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.7yrs | US$9.78m | no data | |
| Chairman of the Board | 10.3yrs | US$216.44k | 0% $ 0 | |
| Non-Executive Director | 10.6yrs | US$206.44k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | 10.3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 9.8yrs | US$227.69k | 0% $ 0 | |
| Independent Director | 6.7yrs | US$251.74k | 0% $ 0 | |
| Independent Director | 9.4yrs | US$287.69k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data |
Experienced Board: CKPT's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/03 16:52 |
| End of Day Share Price | 2025/05/29 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Checkpoint Therapeutics, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Justin Walsh | B. Riley Securities, Inc. |
| Jason Kolbert | D. Boral Capital LLC. |